Featured Research

from universities, journals, and other organizations

Columbia Presbyterian Researchers Show Prostate Cancer Drug Significantly Arrests Tumor Growth With Minimal Side Effects

Date:
October 3, 2001
Source:
Columbia University College Of Physicians And Surgeons
Summary:
The results of a clinical study of the effects of Exisulind, a new drug that has been shown to slow tumor growth in men with advanced prostate cancer, are being published in the September issue of The Journal of Urology. The study is the first of its kind to show a significant effect of a new class of drugs that may stabilize progressive, recurrent disease in patients with advanced prostate cancer.

NEW YORK, NY, - The results of a clinical study of the effects of Exisulind, a new drug that has been shown to slow tumor growth in men with advanced prostate cancer, are being published in the September issue of The Journal of Urology. The study is the first of its kind to show a significant effect of a new class of drugs that may stabilize progressive, recurrent disease in patients with advanced prostate cancer.

"These results suggest that Exisulind may delay disease progression in men with recurrent prostate cancer," says Dr. Erik Goluboff, Assistant Professor of Urology at Columbia University College of Physicians & Surgeons, Director of Urology at The Allen Pavilion of NewYork-Presbyterian Hospital, and the principal investigator of the trial. "This will subsequently prolong the time period between post-surgical PSA rise and the need for androgen deprivation therapies."

Exisulind is from a new class of compounds called selective apoptotic anti-neoplastic drugs (SAANDs). SAANDs inhibit cyclic GMP phosphodiesterase and selectively induce apoptosis (programmed cell death) in abnormally growing pre-cancerous and cancerous cells. Because SAANDs do not induce apoptosis in normal cells, they do not produce most of the adverse reactions or serious side effects normally associated with chemotherapeutic agents used to treat cancer.

Other available therapies, such as drugs, hormones, or radiation, try to limit spread of the disease and increase survival time by shrinking or stabilizing tumors but can impair patient recovery with severe side effects. "For instance, hormonal therapy produces high response rates in metastatic prostate cancer, but patients develop resistance over time," says Dr. Goluboff. "The side effects of hormonal treatment can significantly impact the patient's quality of life. New treatment options that might delay the need for such side effect-prone therapies could provide great benefit in the management of prostate cancer."

Previous studies in mice showed that Exisulind inhibits the growth of prostate cancer by 80 percent to 90 percent. In a related study of patients, researchers found that the drug also causes regression in the growth of precancerous colonic polyps, a condition that often leads to colon cancer.

For 12 months, the trial followed 96 prostate cancer patients who already had their prostate glands removed. All had rising prostate-specific antigen (PSA) levels indicating recurrent disease. Half received Exisulind, and half were given a placebo. The researchers measured the drug's ability to slow or halt disease progression by following patients' PSA levels. High levels of PSA are associated with more aggressive disease.

Imaging tests were performed before and after the study. All of the men were classified into risk groups with no statistical difference in age, race, and weight. The study showed a significant decrease in the rate of rise in PSA in patients given Exisulind compared with placebo.

Almost 185,000 new cases of prostate cancer will be diagnosed in the United States this year. More than 39,000 men will die of the disease, making it the second leading cause of cancer death in men. Although prognosis is good when prostate cancer is detected early, advanced disease, while treatable, has no cure.

Dr. Goluboff cautions that more research needs to be conducted to determine long-term effects in these patients and in other groups of patients with prostate cancer.

The study was funded by Cell Pathways Inc., developer of the drug Exisulind. The company first announced the results of the trial in November 1999.


Story Source:

The above story is based on materials provided by Columbia University College Of Physicians And Surgeons. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University College Of Physicians And Surgeons. "Columbia Presbyterian Researchers Show Prostate Cancer Drug Significantly Arrests Tumor Growth With Minimal Side Effects." ScienceDaily. ScienceDaily, 3 October 2001. <www.sciencedaily.com/releases/2001/10/011003064106.htm>.
Columbia University College Of Physicians And Surgeons. (2001, October 3). Columbia Presbyterian Researchers Show Prostate Cancer Drug Significantly Arrests Tumor Growth With Minimal Side Effects. ScienceDaily. Retrieved August 21, 2014 from www.sciencedaily.com/releases/2001/10/011003064106.htm
Columbia University College Of Physicians And Surgeons. "Columbia Presbyterian Researchers Show Prostate Cancer Drug Significantly Arrests Tumor Growth With Minimal Side Effects." ScienceDaily. www.sciencedaily.com/releases/2001/10/011003064106.htm (accessed August 21, 2014).

Share This




More Health & Medicine News

Thursday, August 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Possible Ebola Patient in Isolation at California Hospital

Possible Ebola Patient in Isolation at California Hospital

Reuters - US Online Video (Aug. 20, 2014) — A patient who may have been exposed to the Ebola virus is in isolation at the Kaiser Permanente South Sacramento Medical Center. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Raw: World's Oldest Man Lives in Japan

Raw: World's Oldest Man Lives in Japan

AP (Aug. 20, 2014) — A 111-year-old Japanese was certified as the world's oldest man by Guinness World Records on Wednesday. Sakari Momoi, a native of Fukushima in northern Japan, was given a certificate at a hospital in Tokyo. (Aug. 20) Video provided by AP
Powered by NewsLook.com
Do More Wedding Guests Make A Happier Marriage?

Do More Wedding Guests Make A Happier Marriage?

Newsy (Aug. 20, 2014) — A new study found couples who had at least 150 guests at their weddings were more likely to report being happy in their marriages. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) — Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins